A J Bathgate

Summary

Country: UK

Publications

  1. ncbi Recommendations for alcohol-related liver disease
    A J Bathgate
    Scottish Liver Transplant Unit, Royal Infirmary of Edinburgh, Edinburgh EH3 9YW, UK
    Lancet 367:2045-6. 2006
  2. ncbi Polymorphisms in tumour necrosis factor alpha, interleukin-10 and transforming growth factor beta1 genes and end-stage liver disease
    A J Bathgate
    Department of Medicine, Royal Infirmary of Edinburgh, UK
    Eur J Gastroenterol Hepatol 12:1329-33. 2000
  3. ncbi Review article: Nucleoside analogues for the treatment of chronic hepatitis B
    H M Younger
    Liver Unit, Royal Infirmary of Edinburgh, Edinburgh, UK
    Aliment Pharmacol Ther 20:1211-30. 2004
  4. ncbi C4d immunopositivity is uncommon in ABO-compatible liver allografts, but correlates partially with lymphocytotoxic antibody status
    C O C Bellamy
    Department of Pathology, Edinburgh Royal Infirmary, 51 Little France Crescent, Edinburgh, UK
    Histopathology 50:739-49. 2007

Collaborators

  • C O C Bellamy
  • H M Younger
  • M M Herriot
  • D J Harrison
  • P C Hayes

Detail Information

Publications4

  1. ncbi Recommendations for alcohol-related liver disease
    A J Bathgate
    Scottish Liver Transplant Unit, Royal Infirmary of Edinburgh, Edinburgh EH3 9YW, UK
    Lancet 367:2045-6. 2006
  2. ncbi Polymorphisms in tumour necrosis factor alpha, interleukin-10 and transforming growth factor beta1 genes and end-stage liver disease
    A J Bathgate
    Department of Medicine, Royal Infirmary of Edinburgh, UK
    Eur J Gastroenterol Hepatol 12:1329-33. 2000
    ..To determine any relationship between polymorphisms in the genes encoding tumour necrosis factor alpha (TNFalpha), interleukin-10 (IL-10) and transforming growth factor beta1 (TGFbeta1) and end-stage liver disease...
  3. ncbi Review article: Nucleoside analogues for the treatment of chronic hepatitis B
    H M Younger
    Liver Unit, Royal Infirmary of Edinburgh, Edinburgh, UK
    Aliment Pharmacol Ther 20:1211-30. 2004
    ..If some of these newer anti-viral agents are approved for use in chronic hepatitis B, the potential for prolonged suppression of hepatitis B virus replication with resultant stabilization or improvement in liver disease may be achieved...
  4. ncbi C4d immunopositivity is uncommon in ABO-compatible liver allografts, but correlates partially with lymphocytotoxic antibody status
    C O C Bellamy
    Department of Pathology, Edinburgh Royal Infirmary, 51 Little France Crescent, Edinburgh, UK
    Histopathology 50:739-49. 2007
    ..To determine whether C4d immunopositivity helps recognition of humoral rejection in dysfunctional liver allografts...